Video brief · 2026-09-09
What Does "Research Use Only" Actually Mean?
Research Use Only sounds like a safety grade. It is not. It is a labelling and marketing category that began with laboratory reagents, antibodies, assay kits and cell lines sold to labs for developing other tests. Regulators separate products marketed for human diagnosis or treatment, which need clearance or an investigational pathway, from products marketed for research, which do not.
The peptide market borrowed that label wholesale. Vials of BPC-157, TB-500 and similar compounds are sold online stamped for laboratory research use only, often beside marketing that plainly assumes a person will use them. The label answers one narrow question, whether this product has been cleared for human use. People read it as answering a broader one: has this compound been studied in humans, and is it safe? It answers neither.
BPC-157 is the clearest case study because its clinical history is short. ClinicalTrials.gov lists one completed human study, NCT02637284, a 2015 Phase 1 pilot in forty-two healthy volunteers that measured only safety and pharmacokinetics of an oral tablet. Its status has sat at Unknown for roughly a decade and no results were posted. A 2026 review in The American Journal of Sports Medicine by Mayfield and colleagues surveyed the most-marketed RUO peptides and concluded that dosing, duration and safety in humans remain unknown for all of them.
A related lesson: a registry listing is not evidence that research is happening. In 2026 a set of template records describing BPC-157, TB-500 and GHK-Cu trials appeared on ClinicalTrials.gov; one stated in its own summary that it was a fictional example. An NCT number proves a form was filled in, nothing more.
The limit of the evidence is simple. No independent, publicly reported purity testing of research-chemical peptide products was found, and the one human BPC-157 trial never reported. The label closes no gap; it marks one.
Sources
- ClinicalTrials.gov. NCT02637284, Phase I pilot study of PCO-02 (BPC-157) in healthy volunteers
- ClinicalTrials.gov 2015
- Mayfield CK, Bolia IK, Feingold CL, et al. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians
- The American Journal of Sports Medicine 2026
Peptide Proof reports what studies found. We do not give medical advice, dosing guidance, or treatment recommendations.